ForSight says it performed the first fully robot assisted cataract surgery on a human in April 2026 using the JASPER surgical robot platform, framed as a capacity fix for a shrinking ophthalmologist workforce.
ForSight Robotics announced in April 2026 that it had performed what it calls the world's first fully robot-assisted cataract surgery on a human, using the JASPER platform. The case was announced on BusinessWire and covered by The Robot Report and Ophthalmology Management. ForSight's framing is a workforce argument: "There is a global shortage of ophthalmic surgeons, and the volume of cataract surgeries is increasing while the surgeon workforce is declining," ForSight co-founder, president, and chief medical officer Dr. Joseph Nathan said in the release.
Cataracts are the world's leading cause of blindness, and surgery (a short outpatient procedure that replaces a clouded lens with an artificial implant) is the only treatment. Cataract surgery is also one of the highest-volume operations performed anywhere. The structural problem is direct: aging populations push demand up while the trained workforce that does the intraocular work has stopped growing.
JASPER runs the full cataract workflow from a separate workstation. The surgeon operates the system; the robot executes the intraocular cuts, lens removal, and implant placement with sub-millimeter precision and motion scaling designed to cut variability and fatigue. ForSight's pitch is that one surgeon on JASPER can supervise more cases per day, with shorter training curves and more consistent outcomes, than manual phacoemulsification with optional femtosecond-laser assistance. ForSight has not released outcomes data from the human case.
ForSight closed a $125 million Series B in June 2025 to push the platform toward regulators and commercial rollout. The first human case sits ten months after that raise.
Intuitive Surgical's da Vinci platform built an earlier generation's urology franchise on a similar argument: one console, more cases per surgeon per day. Cataract surgery is a higher-volume specialty than urology, so the workforce-capacity case applies more sharply in ophthalmology than it did in early robot-assisted urology.
The "world's first" claim is ForSight-attributed. No independent surgical society, peer-reviewed journal, or regulator has, in the publicly reviewed coverage, corroborated the milestone or published complication rates. Terminology is also inconsistent across the coverage: the company press release and most outlets describe the case as "fully robot-assisted," while some write-ups use "fully robotic." Both are distinct from laser-assisted cataract platforms such as LenSx and Catalys, which automate parts of the procedure but stop short of the intraocular manipulation JASPER claims.
A single first-in-human case proves the system can run on a live patient. It does not yet prove outcomes at scale. The next milestones are outcomes data: complication rates against manual and laser-assisted baselines, supervising case volume per surgeon per day, and the regulatory sequence. CE marking in Europe, or approvals in markets with established ophthalmic surgical volume such as India.
ForSight's pitch pulls hardest on markets where the ophthalmologist-to-patient ratio is steepest. Large parts of South and Southeast Asia and sub-Saharan Africa already run high-volume cataract surgery per surgeon, and the workforce-capacity math argues for a robotic platform on sharper ground there than in the U.S. or Europe. The remaining test is whether outcomes hold across the patient mix seen in those markets.
Cataract surgery is the largest single category of elective surgery on earth. The benchmark for JASPER is whether one surgeon can reliably handle more cases per day, with comparable or better outcomes, than manual phacoemulsification. ForSight has not yet published the data to answer that question.